Quick Takeaways
- This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 14 Sep 2022, 17:10.
PATRICK DEVAL L - 12 Sep 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Role
- Director
- Signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
- Issuer symbol
- N/A
- Transactions as of
- 12 Sep 2022
- Net transactions value
- -$866,385
- Form type
- 4
- Filing time
- 14 Sep 2022, 17:10:13 UTC
- Previous filing
- 17 Jun 2022
- Next filing
- 19 Sep 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 14 Sep 2022."
What Changed
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: -$866,385.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Common Stock | Options Exercise | $602,037 | +47,705 | $12.62 | 47,705 | 12 Sep 2022 | Direct | F1 | |
| transaction | CERE | Common Stock | Sale | $1,468,422 | -47,705 | -100% | $30.78 | 0 | 12 Sep 2022 | Direct | F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Stock Option (Right to Buy) | Options Exercise | $0 | -47,705 | -53% | $0.000000 | 42,685 | 12 Sep 2022 | Common Stock | 47,705 | $12.62 | Direct | F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. |
| F2 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.29 - $31.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021. |